. Author manuscript; available in PMC: 2014 Jun 5.

Published in final edited form as: Am J Gastroenterol. 2014 Jan 14;109(3):357–368. doi: 10.1038/ajg.2013.443

Table E2.

Assessment of additive interaction between Helicobacter pylori and corpus gastritis or acid reduction medication (weekly H2RA or PPI use) on BE

Variable	Estimate (s.e.)	Wald χ² (P value)^a
Unadjusted
H. pylori	–0.02 (0.16)	0.02 (0.90)
Corpus gastritis or weekly acid reduction medication (H2RA or PPI)	0.29 (0.04)	48.7 (<0.0001)
Interaction between H. pylori and corpus gastritis or weekly acid reduction medication	–0.27 (0.16)	2.72 (0.10)
Adjusted^a
H. pylori	–0.03 (0.02)	0.02 (0.88)
Corpus gastritis or weekly acid reduction medication (H2RA or PPI)	0.25 (0.04)	39.8 (<0.0001)
Interaction between H. pylori and corpus gastritis or weekly acid reduction medication	–0.16 (0.21)	0.52 (0.47)

BE, Barrett's esophagus; H2RA, H2 receptor antagonist; PPI, proton pump inhibitor.

Controlling for age and non-Hispanic white race.